What’s the current market cap for Protagonist Therapeutics stock?

Protagonist Therapeutics (PTGX) has a market cap of $7.3bn as of June 20, 2026.

What is the P/E ratio for Protagonist Therapeutics stock?

The price to earnings (P/E) ratio for Protagonist Therapeutics (PTGX) stock is 0 as of June 20, 2026.

Does Protagonist Therapeutics stock pay dividends?

No, Protagonist Therapeutics (PTGX) stock does not pay dividends to its shareholders as of June 20, 2026.

When is the next Protagonist Therapeutics dividend payment date?

Protagonist Therapeutics (PTGX) stock does not pay dividends to its shareholders.

What is the beta indicator for Protagonist Therapeutics?

Protagonist Therapeutics (PTGX) has a beta rating of 1.83. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy Protagonist Therapeutics stock | $PTGX Share Price

13:30

15:10

16:45

18:25

20:00

About Protagonist Therapeutics

Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.

Ticker

$PTGX

Sector

Health

Primary listing

NASDAQ

Employees

131

Headquarters

Newark, United States

Website

www.protagonist-inc.com

PTGX Metrics

BasicAdvanced

$7.3bn

-$1.79

1.83

What the Analysts think about PTGX

Analyst ratings (Buy, Hold, Sell) for Protagonist Therapeutics stock.

Bulls say / Bears say

The FDA accepted the rusfertide NDA and granted Priority Review with a PDUFA goal date in Q3 2026, providing a clear near-term regulatory catalyst and path to first-in-class approval (AFP)

On April 28 2026, Protagonist exercised its U.S. collaboration opt-out right with Takeda, triggering a $200 million upfront payment and entitling the company to up to $400 million in opt-out fees, a $75 million approval milestone, and tiered worldwide royalties of 14%–29%, substantially enhancing near-term non-dilutive cash flows (Nasdaq)

Protagonist’s two lead peptides, rusfertide and icotrokinra, are in advanced Phase III clinical development with NDAs under review, underscoring a de-risked late-stage pipeline poised for potential 2026 approvals (FT)

Q4 2025 license and collaboration revenue plunged to $7.44 million, down 95.7% year-over-year, highlighting the lumpy, milestone-dependent nature of Protagonist’s revenue stream (Reuters via Sahm)

Protagonist reported a Q4 2025 net loss of $44.4 million and a full-year 2025 net loss of $130.1 million, underscoring continued unprofitability outside of milestone payments (Reuters via Sahm)

R&D expenses rose in Q4 2025 due to increased pre-clinical research in IL-17 and obesity programs, potentially accelerating cash burn ahead of product revenue (Reuters via Sahm)

Data summarised monthly by Lightyear AI. Last updated on 17 Jun 2026.

PTGX Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

PTGX Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Bulls say / Bears say

The FDA accepted the rusfertide NDA and granted Priority Review with a PDUFA goal date in Q3 2026, providing a clear near-term regulatory catalyst and path to first-in-class approval (AFP)

Q4 2025 license and collaboration revenue plunged to $7.44 million, down 95.7% year-over-year, highlighting the lumpy, milestone-dependent nature of Protagonist’s revenue stream (Reuters via Sahm)

Protagonist reported a Q4 2025 net loss of $44.4 million and a full-year 2025 net loss of $130.1 million, underscoring continued unprofitability outside of milestone payments (Reuters via Sahm)

R&D expenses rose in Q4 2025 due to increased pre-clinical research in IL-17 and obesity programs, potentially accelerating cash burn ahead of product revenue (Reuters via Sahm)

Data summarised monthly by Lightyear AI. Last updated on 17 Jun 2026.

About Protagonist Therapeutics

Ticker

Employees

PTGX Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about PTGX

Analyst Ratings

Bulls say / Bears say

PTGX Financial Performance

Income Statement

PTGX Earnings Performance

Earnings per share (EPS)

PTGX News

Protagonist Therapeutics Reports Granting of Inducement Awards

Protagonist Therapeutics to Present Phase 3 VERIFY and Long-Term Rusfertide Data at the 2026 European Hematology Association Congress

Protagonist Therapeutics to Participate in Two Investment Bank Conferences in June 2026

Buy $PTGX

Lightyear

Legal

Work with us

Bulls say / Bears say

Protagonist Therapeutics/$PTGX

About Protagonist Therapeutics

Ticker

Employees

PTGX Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

What the Analysts think about PTGX

Analyst Ratings

Bulls say / Bears say

PTGX Financial Performance

Income Statement

PTGX Earnings Performance

Earnings per share (EPS)

PTGX News

Protagonist Therapeutics Reports Granting of Inducement Awards

Protagonist Therapeutics to Present Phase 3 VERIFY and Long-Term Rusfertide Data at the 2026 European Hematology Association Congress

Protagonist Therapeutics to Participate in Two Investment Bank Conferences in June 2026

What’s the current market cap for Protagonist Therapeutics stock?

What is the P/E ratio for Protagonist Therapeutics stock?

Does Protagonist Therapeutics stock pay dividends?

When is the next Protagonist Therapeutics dividend payment date?

What is the beta indicator for Protagonist Therapeutics?

Bulls say / Bears say